Page 300 - Demo

Chapter 9298References1. Van Eeghen AM, Bruining H, Wolf NI, Bergen AA, Houtkooper RH, Van Haelst MM, et al. Personalized medicine for rare neurogenetic disorders: can we make it happen? Cold Spring Harb Mol Case Stud. 2022;8(2):a006200. 2. Strydom A, Coppus A, Blesa R, Danek A, Fortea J, Hardy J, et al. Alzheimer’s disease in Down syndrome: An overlooked population for prevention trials. Vol. 4, Alzheimer’s and Dementia: Translational Research and Clinical Interventions. 2018. 3. Efron D, Taylor K, Payne JM, Freeman JL, Cranswick N, Mulraney M, et al. Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial. BMJ Open. 2020. 4. Heussler H, Cohen J, Silove N, Tich N, Bonn-Miller MO, Du W, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord. 2019. 5. Tartaglia N, Bonn-Miller M, Hagerman R. Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature. Cannabis and Cannabinoid Research. 2019. 6. Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3. 7. Palumbo JM, Thomas BF, Budimirovic D, Siegel S, Tassone F, Hagerman R, et al. Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment. J Neurodev Disord. 2023;15(1):1–10. 8. De Kuijper G, Evenhuis H, Minderaa RB, Hoekstra PJ. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. J Intellect Disabil Res. 2014. 9. Cheon KA, Ryu YH, Kim JW, Cho DY. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: Relating to treatment response to methylphenidate. Eur Neuropsychopharmacol. 2005;15(1). 10. Laje G, Bernert R, Morse R, Pao M, Smith ACM. Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome. Am J Med Genet Part C Semin Med Genet. 2010.11. van der Poest Clement E, Jansen FE, Braun KPJ, Peters JM. Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex. Pediatric Drugs. 2020. 12. Curatolo P, Bjørnvold M, Dill PE, Ferreira JC, Feucht M, Hertzberg C, et al. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Drugs. 2016;76(5). 13. Morrissey H, Pradhan T. Escitalopram in the treatment of anxiety in chromosome 18p deletion. Vol. 28, Journal of Child and Adolescent Psychopharmacology. 2018. 14. Stockler-Ipsiroglu S, Potter BK, Yuskiv N, Tingley K, Patterson M, van Karnebeek C. Developments in evidence creation for treatments of inborn errors of metabolism. Vol. 44, Journal of Inherited Metabolic Disease. 2021. 15. Erickson CA, Davenport MH, Schaefer TL, Wink LK, Pedapati E V., Sweeney JA, et al. Fragile X targeted pharmacotherapy: Lessons learned and future directions. Vol. 9, Journal of Neurodevelopmental Disorders. 2017. 16. Overwater IE, Rietman AB, Mous SE, Bindels-De Heus K, Rizopoulos D, Ten Hoopen LW, et al. A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex. Neurology. 2019. 17. Tate RL, Perdices M. Single-Case Experimental Designs for Clinical Research and Neurorehabilitation Settings. Single-Case Experimental Designs for Clinical Research and Neurorehabilitation Settings. 2019. Annelieke Muller sHL.indd 298 14-11-2023 09:08